The effect of liposomal cefoperazone against Pseudomonas aeruginosa in a granulocytopenic mouse model of acute lung infection. 1992

P H Di Rocco, and M C Nacucchio, and D O Sordelli, and F Mancuso, and A M Hooke
Departamento de Tecnología Farmacéutica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Argentina.

The therapeutic efficacy of liposomal cefoperazone against Pseudomonas aeruginosa was investigated in a granulocytopenic mouse model of acute lung infection. Granulocytopenia was induced in mice by intraperitoneal (i.p.) injection of 200 mg/kg cyclophosphamide. Mice were challenged by exposure to an aerosol containing P. aeruginosa and were treated i.p. with liposomal cefoperazone prepared by the dehydration-rehydration method. The half-life of free cefoperazone in the lungs following i.p. administration of the liposomal drug was significantly lengthened (13 min vs. 261 min), and the cefoperazone activity in the lungs remained above the MIC longer after administration of liposomal cefoperazone than after treatment with cefoperazone. Liposomal cefoperazone was more effective than cefoperazone alone in preventing death of granulocytopenic mice from lethal pulmonary challenge with P. aeruginosa (75% vs. 38% survival, p = 0.031). Finally, P. aeruginosa was cleared faster from the lungs of mice treated with liposomal cefoperazone when compared with those treated with cefoperazone. This study shows that incorporation of cefoperazone into liposomes enhances the activity of the antibiotic against P. aeruginosa in a granulocytopenic host.

UI MeSH Term Description Entries
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008171 Lung Diseases Pathological processes involving any part of the LUNG. Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002438 Cefoperazone Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections. Cefobid,Cefoperazon,Cefoperazone Sodium,Cefoperazone Sodium Salt,Céfobis,T-1551,T1551,Salt, Cefoperazone Sodium,Sodium Salt, Cefoperazone,Sodium, Cefoperazone,T 1551
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000380 Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS). Granulocytopenia,Agranulocytoses,Granulocytopenias
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

P H Di Rocco, and M C Nacucchio, and D O Sordelli, and F Mancuso, and A M Hooke
September 1993, Antimicrobial agents and chemotherapy,
P H Di Rocco, and M C Nacucchio, and D O Sordelli, and F Mancuso, and A M Hooke
November 1994, Clinical immunology and immunopathology,
P H Di Rocco, and M C Nacucchio, and D O Sordelli, and F Mancuso, and A M Hooke
November 2002, Biochemical pharmacology,
P H Di Rocco, and M C Nacucchio, and D O Sordelli, and F Mancuso, and A M Hooke
May 2018, Toxins,
P H Di Rocco, and M C Nacucchio, and D O Sordelli, and F Mancuso, and A M Hooke
August 1986, The Journal of clinical investigation,
P H Di Rocco, and M C Nacucchio, and D O Sordelli, and F Mancuso, and A M Hooke
March 2017, Antimicrobial agents and chemotherapy,
P H Di Rocco, and M C Nacucchio, and D O Sordelli, and F Mancuso, and A M Hooke
September 2003, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
P H Di Rocco, and M C Nacucchio, and D O Sordelli, and F Mancuso, and A M Hooke
November 2020, Bio-protocol,
P H Di Rocco, and M C Nacucchio, and D O Sordelli, and F Mancuso, and A M Hooke
June 1986, Israel journal of medical sciences,
P H Di Rocco, and M C Nacucchio, and D O Sordelli, and F Mancuso, and A M Hooke
January 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
Copied contents to your clipboard!